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Clinical depressionBackground:Depression is a risk factor formortality in patientswith heart failure (HF), however, treating depres-
sion with antidepressant therapy does not seem to improve survival. We examined the prevalence of
antidepressant use in HF patients, the correlates of antidepressant use subsequent to hospital discharge and
the relation between antidepressant use, clinical depression and mortality in patients with HF.
Methods: 121,252 HF patients surviving ﬁrst hospitalizationwere stratiﬁed by antidepressant use and a diagnosis
of clinical depression.
Results: In total, 15.6% (19,348) received antidepressants at baseline, of which 86.7% (16,780) had no diagnosis of
clinical depression. Female gender, older age, higher socio-economic status,more comorbidities, increased use of
statins, spironolactone and aspirin, lower use of beta-blockers and ACE-inhibitors, greater HF severity and a diag-
nosis of clinical depression were independently associated with antidepressant use. Patients using no
antidepressants with clinical depression and patients using antidepressants, with or without clinical depression,
had a signiﬁcantly higher risk for all-causemortality (HR, 1.25; 95% CI, 1.15–1.36; HR, 1.24; 95% CI, 1.22–1.27;HR,
1.21; 95% CI, 1.16–1.27, respectively) and CV-mortality (HR: 1.17; 95% CI, 1.14–1.20, P b .001; HR: 1.20; 95% CI,
1.08–1.34, P b .001; HR: 1.21; 95% CI, 1.12–1.29, P b .001, respectively) as compared to patients not using
antidepressants without depression in adjusted analysis.
Conclusion: Patients with HF taking antidepressants had an increased risk for all-cause and CV-mortality,
irrespectively of having clinical depression. These results highlight the importance of further examining the
antidepressant prescription pattern in patients with HF, as this may be crucial in understanding the
antidepressant effects on cardiac function and mortality.
© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Depression is prevalent in 15%–40% of patients with heart failure
(HF) and increases the risk for mortality and re-hospitalization [1,2].
Given the assumption that treating depression in HF would improve
prognosis, there has been a considerable rise in antidepressant use in
these patients over the past years [1,3,4]. Paradoxically, effectively
treating depression with antidepressant therapy does not seem to be a
guarantee for successfully reducing the risk for adverse events in pa-
tients with cardiovascular disease [5,6], with some studies evenniversity of SouthernDenmark,
en).
.suggesting an increased risk for HF mortality [3,7]. The association be-
tween antidepressant use and cardiovascular events appears to depend
on the class of antidepressant medication [8], and may vary across dif-
ferent cardiovascular populations, deﬁnitions of antidepressant use
and statistical analyses used [1]. Not all studies adjusted statistically
for depressive symptoms, nor examined the combined effect of
antidepressant use and depressive symptoms [9–12], let alone included
a diagnosis of clinical depression.
The two main classes of antidepressant medication are the selective
serotonin reuptake inhibitors (SSRIs) and the tricyclic antidepressants
(TCAs) [1]. TCAs are known to have pharmacological properties that
can precipitate life-threatening arrhythmias, increase heart rate and or-
thostatic hypotension and prolong QT-interval in patients with ischemic
heart disease [13]. Despite these side effects only a few studies found that
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mic heart disease [10] and myocardial infarction [9] in population-based
samples, or mortality in patients with pre-existing HF [3].
Findings on SSRIs suggest that their use in cardiac patients is rela-
tively safe and induces only minimal cardiovascular effects, making
them preferable over TCAs [13]. Two studies conﬁrmed the safety of
SSRIs by showing reduced incidence of myocardial infarction or mortal-
ity in HF patients using SSRIs [14,15]. However, other studies found no
signiﬁcant difference in risk in relation to SSRI use [5,8–12].
Given these gaps in our knowledge, there is an urgent need to re-
examine the prescription pattern of antidepressants post HF diagnosis
and the mortality risk associated with antidepressant use in large co-
horts of HF patients in order to optimize the treatment and care for
these patients. Hence, the objectives of the current studywere to (1) ex-
amine the prevalence of antidepressant use in HF patients 5-years post
diagnosis, (2) identify the correlates of antidepressant use subsequent
to hospital discharge, and (3) examine the relation between
antidepressant use and both all-cause and cardiovascular (CV)mortality
in a large sample of HF patients. Information on HF diagnosis, use and
type of antidepressant, and clinical diagnosis of depression was derived
from the Danish registries. These registries provide a unique opportuni-
ty to track antidepressant use over time and to examinewhether the as-
sociation between antidepressant use and mortality is similar in HF
patients with and without a clinical diagnosis of depression, while con-
trolling for potential confounders.
2. Methods
2.1. Data sources and study population
The Danish National Health Service provides tax-supported health care, which allows
access to general practitioners and hospitals, and partially reimburses prescribed drugs.
Using the civil registry number, which is unique to every Danish citizen, it is possible to
perform a complete linkage of all administrative population-based registries at the indi-
vidual level. The Danish registries include data on socio-demographic characteristics,
socio-economic status, hospitalizations, vital status, and prescribedmedications. Vital sta-
tus was obtained from the Danish Civil Registration System. Diagnostic information from
hospital admissions are coded using the International Classiﬁcation of Diseases, Tenth Re-
vision (ICD-10), and drugs were grouped according to Anatomical Therapeutic Chemical
(ATC) codes.
2.2. Study population
For this study, we obtained information from all individuals who survived their ﬁrst
hospital admission for HF between 1997 and 2010 (ICD-codes: I11.0, I50, I42, and J81).
First time admissionwas deﬁned as no previous admission for HF since 1978. The registry
did not allow us to distinguish between HF with preserved or reduced ejection fraction. A
diagnosis of clinical depression included unipolar depression (i.e., major depressive epi-
sode, dysthymia) (ICD-codes: DF32-DF39). The prevalence of clinical depression was ex-
tracted from the registry at 90 days after discharge and at 1- and 5-year follow-up. To
ensure equal time for all patients to claim prescriptions for new medications after hospi-
talization, we only included patients alive 90 days after discharge. This approach has
been used in previous Danish studies that have included information on medication pre-
scriptions [3]. The observational time started 90 days after discharge (from now on re-
ferred to as ‘study baseline’) and followed patients at risk for all-cause and CV mortality
until December 31st 2010.
2.3. Medical treatment: Cardiac and antidepressant medication
We used the following ATC codes to identify the use of antidepressants (N06A), beta-
blockers (C07), statins (C10A), loop diuretics (C03C), spironolactone (C03D), aspirin
(B01AC06) and angiotensin-converting enzyme (ACE) inhibitors (C09). The use of
antidepressant and cardiac medications was deﬁned as at least 1 claimed prescription
within 90 days after discharge. The use of antidepressants was also examined at 1- and
5-year follow-up.
2.4. Statistical analysis
All continuous variables were tested for normal distribution. Continuous and categori-
cal variableswere described by the presence or absence of clinical depression and/or the use
of antidepressant medication. Statistical comparisons were made between groups using
Pearson's Chi-square test for categorical variables and analysis of variance for continuous
variables. Multivariable logistic regression was used to examine the correlates of
antidepressant use, thereby including age, gender, socio-economic status, days of hospital-
ization, comorbidity (Charlson's Comorbidity Index version 9.5.12), HF severity, othercardiacmedications (i.e., beta-blockers, statins, ACE-inhibitors), and clinical diagnosis of de-
pression. To determine the severity of HF, the average daily dosage of loop diuretics in the
ﬁrst 90 days after discharge was calculated (group I: 0–39 mg; group II: 40–80 mg; group
III: 81–160 mg; group IV: N160 mg) [3]. Socio-economic status was calculated using the
family income 5 years before the ﬁrst diagnosis of HF, divided by the number of family
members. All incomes were then divided into quintiles to generate equal size income
groups.
Kaplan–Meier plots and multivariable Cox proportional hazard regression analysis
were used to compare all-cause and CVmortality stratiﬁed by antidepressant use and clin-
ical diagnosis of depression for the following 4 groups: (1) patients using no
antidepressants with no clinical diagnosis of depression, (2) patients using no
antidepressants with a clinical diagnosis of depression, (3) patients using
antidepressants with no clinical diagnosis of depression, and (3) patients using
antidepressants with a clinical diagnosis of depression. Multivariable models were ﬁtted
with socio-demographic (age, gender, marital status), socio-economic and clinical vari-
ables (days of hospitalization, comorbidity, HF severity, cardiac medication). Another
Cox proportional hazard regression analysis was performed examining the impact of the
use of different antidepressant groups (i.e., TCAs, SSRI, other (tetra, NaSSA, SNRI)) as com-
pared to no antidepressant use, and on the impact of different types of antidepressants on
all-cause and CVmortality. All analyseswere performed using the Stata statistical package
version 11.2 (Stata Corp, College Station, Tex).2.5. Ethics
The Danish Data Protection Agency approved the study (No. 2003–54-1269). In
Denmark, historical cohort studies based on data from administrative registers do not re-
quire further ethics approval.3. Results
3.1. Baseline characteristics
A total of 121,252 patients survived their ﬁrst hospitalization for HF
during the study period. Baseline characteristics of patients in the total
sample and stratiﬁed by antidepressant use at baseline (90 days after
discharge) are shown in Table 1. Of all patients, 84.4% (101,904) re-
ceived no antidepressants, of which 99.2% (101,095) had no clinical de-
pression, while 0.8% (809) had clinical depression. The remaining 15.6%
(19,348) received antidepressants, of which 13.3% (2568) had a diagno-
sis of clinical depression, while 86.7% (16,780) of the patients did not.
At 1-year, 98,590 patients were still alive, with 22.6% (22,281) re-
ceiving antidepressant treatment while only 2.0% (1972) of these pa-
tients also had a diagnosis of clinical depression. At 5 years, 37,813
patients were still alive, of which 32.0% (12,100) received
antidepressant treatment, while only 1% (378) of these patients also
had a diagnosis of clinical depression.3.2. Correlates of antidepressant use
In themultivariable logistic regression analysis, female gender, older
age, higher socio-economic status, more comorbidities, increased use of
statin, spironolactone and aspirin, lower use of beta-blockers and ACE-
inhibitors, greater HF severity and a diagnosis of clinical depression
were independently associated with antidepressant use subsequent to
discharge (Table 2).3.3. Incidence of all-cause and CV mortality during the follow-up period
The median follow-up duration was 2.9 years (interquartile range
1.1–5.6 years). During this period, 61.1% (61,800) of the patients died
due to all-cause mortality in the group of no antidepressants and no
clinical depression, 68.2% (552) of the patients died in the group no
antidepressants with clinical depression, 70.3% (11,801) died in the
group using antidepressants without clinical depression, and 71.3%
(21,830) patients died in the group using antidepressants with clinical
depression (P b .001). The 1-, 3- and 5-year crude all-cause mortality
rates were 19.0%, 49.3% and 69.8%.
Table 1
Baseline characteristics for the total sample and stratiﬁed according to antidepressant use at baseline (90 days after discharge).
Total sample n = 121,252 No antidepressant use n = 101,904 Antidepressant use n = 19,348 P-value
No depression Depression No depression Depression
n = 101,095 n = 809 n = 16,780 n = 2568
Age (mean, SD) 73.5 ± 13.6 73.0 ± 14.6 74.8 ± 11.5 74.0 ± 12.3 77.3 ± 10.8 b.001
Sex, males 64,342 (53.3%) 56,502 (55.9%) 320 (39.6%) 6950 (41.4%) 1210 (35.8%) b.001
Socio-economic status b.001
0 22,683 (18.7%) 19,172 (19.1%) 114 (14.1%) 3002 (17.9%) 392 (15.3%)
1 23,144 (19.1%) 18,847 (18.6%) 176 (21.6%) 3525 (21.0%) 606 (23.6%)
2 23,806 (19.5%) 19,166 (18.9%) 193 (23.9%) 3793 (22.6%) 652 (25.4%)
3 24,746 (20.4%) 20,452 (20.3%) 190 (23.5%) 3557 (21.2%) 548 (21.3%)
4 26,873 (22.3%) 23,458 (23.3%) 136 (16.9%) 2903 (17.3%) 370 (14.4%)
HF Severity groupa b.001
I 45,492 (37.5%) 38,694 (38.3%) 333 (41.2%) 5558 (33.1%) 916 (35.3%)
II 31,424 (25.9%) 26,778 (26.5%) 175 (31.8%) 3931 (23.4%) 513 (21.0%)
III 22,724 (18.7%) 18,460 (18.3%) 146 (39.2%) 3576 (21.3%) 551 (21.1%)
IV 21,612 (17.8%) 17,163 (17.0%) 155 (17.9%) 3715 (22.1%) 588 (22.6%)
Medication after discharge
Βeta-blockers 51,094 (42.1%) 43,864 (43.4%) 257 (31.8%) 6206 (37.0%) 767 (29.9%) b.001
Statins 28,707 (23.7%) 24,238 (24.0%) 132 (16.4%) 3799 (22.6%) 538 (21.0%) b.001
ACE-inhibitors 63,910 (52.7%) 54,578 (54.0%) 317 (39.2%) 7981 (47.5%) 1034 (40.3%) b.001
Spironolactone 26,514 (21.9%) 22,080 (21.8%) 145 (17.9%) 3799 (22.6%) 490 (19.1%) b.001
Aspirin 55,183 (45.5%) 45,686 (45.2%) 293 (36.2%) 8000 (47.7%) 1204 (46.9%) b.001
Comorbidity and history
Myocardial infarction 30,671 (25.3%) 25,887 (25.4%) 217 (26.8%) 4155 (24.8%) 611 (23.8%) .063
Ischemic heart disease 39,941 (32.9%) 33,695 (33.0%) 251 (31.0%) 5541 (33.0%) 806 (31.4%) .233
Comorbidity Index
0 57,083 (47.1%) 49,246 (49.7%) 194 (24.0%) 5974 (35.6%) 669 (26.1%) b.001
1 30,544 (25.2%) 24,753 (24.5%) 223 (27.6%) 4784 (28.5%) 784 (30.5%)
2 13,789 (11.4%) 10,820 (10.7%) 138 (17.1%) 2393 (14.3%) 438 (17.1%)
3 9319 (7.7%) 7425 (7.3%) 105 (13.0%) 1531 (9.1%) 258 (10.1%)
4 5217 (4.3%) 3891 (3.9%) 80 (9.9%) 1034 (6.2%) 212 (8.3%)
≥5 5300 (4.4%) 4960 (3.9%) 69 (8.5%) 1064 (6.3%) 207 (8.1%)
Hospitalization (days, mean, SD) 46.0 ± 85.5 38.0 ± 73.0 49.8 ± 85.5 57.5 ± 100.1 41.4 ± 76.3 b.001
Data are represented as mean ± SD or n (%).
a According to average daily dosage of loop diuretic (furosemide) in the ﬁrst 90 days after discharge (group 1, 0–39 mg; group 2, 40–80 mg; group 3, 81–160 mg; group 4, N160 mg).
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Univariable Cox proportional hazard regression analysis showed
that patients using no antidepressants with clinical depression
(HR: 1.55; 95% CI, 1.42–1.68, P b .001), patients using antidepressants
without clinical depression (HR: 1.45; 95% CI, 1.43–1.48, P b .001), and
patients using antidepressants with clinical depression (HR: 1.68; 95%
CI, 1.60–1.76, P b .001) had a greater risk of all-cause mortality in com-
parison to HF patients not using antidepressants and having no clinical
depression (Fig. 1). Also in multivariable Cox proportional hazard anal-
yses, patients not using antidepressants with clinical depression andTable 2
Associates of antidepressant use at baseline (90 days after discharge) in order of relative
importanceb
OR 95% CI P-value
Clinical depression 4.03 3.87–4.20 b.001
Comorbiditya 1.18 1.16–1.19 b.001
Aspirin 1.15 1.09–1.19 b.001
HF severityc 1.10 1.09–1.12 b.001
Spironolactone 1.07 1.03–1.11 b.001
Statins 1.05 1.00–1.09 .028
Socio-economic status 1.03 1.01–1.04 b.001
Age 1.01 1.00–1.02 b.001
Ischemic etiology 1.00 .97–1.04 .86
Hospitalization days .99 .99–1.00 b.001
ACE-inhibitors .87 .84–.90 b.001
Beta-blockers .83 .80–.86 b.001
Sex (males) .59 .57–.61 b.001
a The Charlson Comorbidity Index was entered as a nominal variable (see Table 1).
b n = 120,453 due to missing data on predictor variables.
c According to average daily dosage of loop diuretic (furosemide) in the ﬁrst 90 days after
discharge (group 1, 0–39 mg; group 2, 40–80 mg; group 3, 81–160 mg; group 4, N160 mg).patients using antidepressants, with or without clinical depression,
had a signiﬁcantly higher risk for all-cause mortality (Ps b .001) com-
pared to patients not using antidepressants without clinical depression
(Table 3) Also in relation to CV-mortality, the univariable Cox propor-
tional hazard analyses showed that patients using no antidepressants
with clinical depression (HR: 1.23; 95% CI, 1.20–1.26, P b .001), patients
using antidepressants without clinical depression (HR: 1.27; 95% CI,
1.40–1.42, P b .001), and patients using antidepressantswith clinical de-
pression (HR: 1.33; 95% CI, 1.26–1.42, P b .001) had a greater risk of
mortality in comparison to HF patients not using antidepressants and
having no clinical depression. These results remained signiﬁcant in the
multivariable Cox proportional hazard analyses (Ps b .001). When ex-
cluding the group of patients not using antidepressants without clinical
depression, there was no longer a signiﬁcant difference in all-cause or
CV-mortality between the remaining groups (Ps N .27).
3.5. Antidepressant groups and all-cause and CV mortality
In order to examine whether groups of anti-depressants (i.e., TCA,
SSRI, other (tetracyclic, NaSSA, SNRI) were associated with a differential
risk for all-cause and CVmortality, a univariable Cox proportional regres-
sion hazard analysis was performed for patients using antidepressants,
stratiﬁed by group of antidepressants, using no antidepressant use as
the reference category. Use of SSRIs (HR: 1.53; 1.49–1.56, P b .001),
TCAs (HR: 1.18; 1.12–1.24, P b .001), other antidepressants (HR: 1.50;
1.44–1.56, P b .001) and a combination of antidepressants (HR: 1.57;
1.49–1.67, P b .001) was associated with an increased all-cause mortality
risk compared to no antidepressant use (Fig. 2). In adjusted analysis, there
remained a signiﬁcant increased all-cause mortality risk for all
antidepressant groups (P b .001 for all) (Table 4). In relation to CVmortal-
ity the use of SSRIs (HR:0.89; 0.87–0.91, P b .001), TCAs (HR:0.90; 0.86–
0.95, P b .001), other antidepressants (HR:0.78; 0.75–0.81, P b .001) and
Fig. 1. Association between clinical depression and antidepressant use (at 90 days) and all-cause mortality (Kaplan Meier survival curve)*. *Reference group is no anti-depressant, no
depression.
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ciated with a decreased risk, which remained similar after correction for
socio-demographic, socio-economic and clinical covariates (Table 4).
A similar analysis was performedwithin the group of antidepressant
users only (n = 19,348), with SSRI used as reference category. InTable 3
Association between clinical depression, antidepressant use (at 90 days) and all-cause and
CV mortality (multivariable Cox proportional hazard analysis)a,b.
Variables All-cause mortality CV mortality
HR 95% CI P value HR 95% CI P value
Group
No antidepressants,
depression
1.25 1.15–1.36 b.001 1.17 1.14–1.20 b.001
Antidepressants,
no depression
1.24 1.22–1.27 b.001 1.20 1.08–1.34 b.001
Antidepressants,
depression
1.21 1.16–1.27 b.001 1.21 1.12–1.29 b.001
Sex (males) 1.27 1.25–1.29 b.001 1.17 1.15–1.20 b.001
Age 1.05 1.04–1.05 b.001 1.02 1.02–1.03 b.001
Socio-economic statusa
1 1.02 .99–1.04 .116 1.05 1.02– 1.07 b.001
2 1.03 1.01– 1.06 .002 1.10 1.07–1.13 b.001
3 .99 .97–1.01 .238 1.06 1.03–1.09 b.001
4 .86 .84–.88 b.001 1.05 1.02–1.08 b.001
Etiology 1.01 .99–1.02 .456 0.98 .96–1.00 0.07
HF severitya
II 1.12 1.09–1.14 b.001 1.05 1.03– 1.08 b.001
III 1.33 1.30–1.36 b.001 1.20 1.17–1.23 b.001
IV 1.66 1.63–1.70 b.001 1.51 1.47–1.55 b.001
Beta-blockers .82 .81–.84 b.001 1.09 1.07–1.11 b.001
ACE-inhibitors .90 .80–.91 b.001 1.06 1.04–1.08 b.001
Spironolactone 1.12 1.10–1.14 b.001 1.17 1.14–1.20 b.001
Statins .78 .76–.79 b.001 1.22 1.19–1.26 b.001
Aspirin 1.00 .99–1.02 .447 1.05 1.03–1.07 b.001
Hospitalization days 1.00 .99–1.00 b.001 0.99 .99–1.00 b.001
Comorbiditya
1 1.36 1.34–1.38 b.001 1.18 1.15–1.20 b.001
2 1.58 1.54–1.61 b.001 1.34 1.30–1.38 b.001
3 1.68 1.64–1.73 b.001 1.41 1.36–1.46 b.001
4 1.99 1.92–2.03 b.001 1.63 1.56–1.70 b.001
≥5 2.20 2.12–2.27 b.001 1.76 1.68–1.83 b.001
a Reference group is lowest group (socio-economic status = 0, HF severity = 1 and co-
morbidity = 0).
b n = 120,453 due to missing data on predictor variables.univariable analysis, use of TCA (HR: 0.78; 0.74–0.82, P b .001) but not
the use of other antidepressants (HR: 0.98; 0.94–1.02, P = .32) and a
combination of antidepressants (HR: 1.03; 0.97–1.09, P = .39) was as-
sociated with a lower all-cause mortality risk compared to SSRI use
(Fig. 3). In adjusted analysis, the use of TCAs remained associated with
a lower all-cause mortality risk compared to SSRI use (P b .001), while
neither the use of other antidepressants (P = .18) nor a combination
of antidepressants (P = .45) was associated with all-cause mortality.
There was no signiﬁcant difference in the risk for CV mortality between
the use of SSRIs and TCAs (HR: 1.02; 0.97–1.07, P = .46). However,
other antidepressants (HR:0.88; 0.84–0.91, P b .001) and a combination
of antidepressants (HR:0.86; 0.86–0.92, P b .001) showed a signiﬁcantly
decreased risk for CV mortality compared to the use of SSRIs.
3.6. Antidepressant type and all-cause and CV mortality
Analyses of individual antidepressants showed that prescriptions
of citalopram (HR: 1.20; 1.17–1.23, P b .001, HR:1.14; 1.11–1.18, P b
.001), escitalopram (HR: 1.28; 1.19–1.37, P b .001, HR:1.58; 1.45–1.73,
P b .001), venlafaxine (HR: 1.16; 1.07–1.25, P b .001, HR:1.12; 1.01–
1.24, P b .001), and mirtazapine (HR: 1.21; 1.16–1.27, P b .001,
HR:1.19; 1.12–1.26, P b .001) at baseline were associated with an in-
creased all-cause and CV mortality risk, respectively. (Table 5).
Fluoxetine (HR: 1.13; 1.03–1.24, P= .01), sertraline (HR: 1.17; 1.11–
1.24, P b .001), nortriptyline (HR: 1.16; 1.04–1.28, P = .005), amitripty-
line (HR: 1.14; 1.06–1.21, P b .001), and duloxetine (HR: 1.39; 1.05–1.85,
P = .02) were only signiﬁcantly associated with increased all-cause
mortality.
4. Discussion
To our knowledge, this is the ﬁrst large-scale study using national
registry data to examine the prevalence of antidepressant use during
5 years of follow-up, and the relationship between antidepressant use
and all-cause and CV mortality in patients with HF, taking into account
a clinical diagnosis of depression and stratifying analyses by
antidepressant group and type. We found a relatively high prevalence
of antidepressant use at baseline, which increased during the 5 years
of follow-up, as was also found in a previous study [5]. In multivariable
regression analyses, the prescription of antidepressants was not only
Fig. 2. Association between antidepressant groups (at 90 days) and all-cause mortality (Kaplan Meier survival curve)*. *Reference group is no antidepressants.
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age, female sex, a higher severity of HF, higher comorbidity burden
and less use of cardiac medications. There were no signiﬁcant differ-
ences between patients with no antidepressant use and clinical depres-
sion versus patients using antidepressants without clinical depression
in adjusted analyses. This suggests that antidepressant use might be a
proxy for unregistered (sub)clinical depression or that antidepressant
use per se could be responsible for the increase in all-cause and CVmor-
tality risk. Given that 86.7% of the patients who were prescribed
antidepressants at baseline had no diagnosis of clinical depression and
antidepressant use was associated with increased mortality risk in this
study, it seems timely to reconsider the administration of
antidepressants in patients with HF, as the magnitude of this mismatch
is not only surprising but also worrisome. Although antidepressants are
prescribed for other disorders than depression, such as anxiety, ﬁbro-
myalgia, chronic pain, and sleep disorders, our results suggest that
their use might come at a considerable cost to patients.
No previous studies have examined the combined effect of clinical
depression and antidepressant use, and studieswhich have investigated
the separate risk of antidepressant use or depression found great vari-
ability in associated risk [5,6,9,10,16,17]. Despite these differences, the
majority of studies found a signiﬁcant increased mortality risk for both
antidepressant use [6,7,9,10,16,17] and clinical depression, separately
[5,6,17]. Some studies were not able to distinguish between the speciﬁcTable 4
Association between type of antidepressant (at 90 days) and all-cause and CV mortality
(multivariable Cox proportional regression hazard analysis)a,b,c.
Variables All-cause mortality CV mortality
HR 95% CI P value HR 95% CI P value
Any SSRI 1.30 1.27–1.33 b.001 .88 .86–.90 b.001
Any TCA 1.23 1.07–1.19 b.001 .92 .88–.96 b.001
Any other antidepressant
(SNRI, NaSSA, tetracylic)
1.41 1.36–1.47 b.001 .80 .77–.83 b.001
Combination of
antidepressants
1.34 1.26–1.42 b.001 .79 .77–.82 b.001
a Reference group is no antidepressant use.
b n = 120,453 due to missing data for predictor variables.
c Analysis controlled for other variables: age, sex, socio-economic status, etiology, HF se-
verity, comorbidity, statin, beta blocker, ACE inhibitor, spironolactone, aspirin, hospitaliza-
tion (days), diagnosis of clinical depression.effect of the antidepressants on mortality in comparison to the effect of
the disorder itself (i.e., depression), as they did not correct for depres-
sion [1,9,10]. Other studies examined the prevalence of depression by
means of self-reported questionnaires, such as the Beck Depression In-
ventory (BDI) and the Geriatric Depression Scale [4,5,17]. The preva-
lence rates of depression in these studies were much higher as
compared to the prevalence of clinical depression that we found in the
current study (20–30% versus 3%, respectively). However, it is generally
known that using self-report measures will lead to a higher prevalence
as compared to a clinical diagnostic interview. Freedland et al. found
that, despite the strong association between the BDI and the classiﬁca-
tions of the Diagnostic and Statistical Manual of Mental Disorders,
only 55% of patients scoring in the depressed range on the BDI had clin-
ically signiﬁcant depression according to the Diagnostic Interview
Schedule, and 16% of patients classiﬁed as non-depressed on the BDI
were depressed according to the Diagnostic Interview Schedule [18].
Besides the differences in the assessment of depression, there were
also differences in the time of assessment, as they asked patients to
complete depression measures during hospitalization. Furthermore, it
could be that depression diagnosed in primary care is not always regis-
tered as clinical depression in the patient registry. Overall, this makes it
difﬁcult to directly compare the ﬁndings.
Subgroup analyses of antidepressants showed that the use of
SSRIs, TCAs, SNRIs, other antidepressants or a combination of
antidepressants at baseline signiﬁcantly increased the risk for all-cause
mortality but decreased the risk for CV mortality in this cohort of HF pa-
tients, also after correction for clinical depression.
This difference inmortality risk is interesting considering the fact that
previous studies have found that TCAs, SSRIs, SNRIs and other
antidepressants may have some pharmacological characteristics which
could potentially increase CV mortality risk rather than decrease this
risk. Antidepressants have been found to precipitate life-threatening ar-
rhythmias, prolong the QT-interval, cause toxicity by drug-drug interac-
tions, and show adverse physiological effects on heart rate variability,
sympathetic control, hypertension and inﬂammation [3,13,19–22].
Alternatively, the elevated overall mortality risk could be explained
by residual confounding due to unmeasured or unknown factors, such
as poor self-care. Equally, it is plausible that a subset of patients suffers
from treatment-resistant depression, in which the antidepressant is not
capable of reducing the depressive symptoms sufﬁciently to decrease
the mortality risk [23].
Fig. 3. Association between antidepressant groups (at 90 days) and all-cause mortality (Kaplan Meier survival curve)*. *Reference group is SSRI.
872 C. Brouwers et al. / International Journal of Cardiology 203 (2016) 867–873When we evaluated the mortality risk using SSRI use as reference
category, the use of TCAs was associated with a 10% reduction in overall
mortality risk in HF patients compared to the use of SSRIs, but showed
no signiﬁcant difference in relation to CV mortality. The results we
found for overall mortality might be explained by a selection bias or un-
measured risk characteristicswhichmay add to the differences between
TCA and SSRI users.
Previous ﬁndings on the effect of individual antidepressants on the
risk of mortality in HF patients were based on the use of
antidepressants at any time during follow-up, and could therefore create
discrepancies in relation to the outcomes of our study. We found that
citalopram, escitalopram, venlafaxine, and mirtazapine at baseline were
associatedwith an increased all-cause and CVmortality risk, respectively.
Fluoxetine, sertraline, nortriptyline, amitriptyline, and duloxetine were
only signiﬁcantly associated with increased all-cause mortality. Overall,
the ﬁnding that four of the SSRIs in our study were found to signiﬁcantly
increase the risk for mortality are surprising, since the use of SSRIs isTable 5
Anti-depressant use (at 90 days) stratiﬁed by type in relation to all-cause and CV mortality (n
Variables Number of patients (%) All-cause mor
Antidepressant use at 90 days HR
SSRIs
Fluoxetine 622 (0.5%) 1.13
Paroxetine 570 (0.5%) 1.08
Sertraline 1633 (1.4%) 1.17
Citalopram 9372 (7.7%) 1.20
Escitalopram 1551 (1.3%) 1.28
TCAs
Nortriptyline 556 (0.5%) 1.16
Amitriptyline 1366 (1.1%) 1.14
Imipramine 289 (0.3%) 1.04
Dosulepine 53 (0.05%) .95
Tetracyclics
Mianserine 26 (0.02%) .98
SNRIs
Venlafaxine 1034 (0.9%) 1.16
Duloxetine 155 (0.1%) 1.39
NaSSAs
Mirtazapine 2789 (2.3%) 1.21
a Reference group is no antidepressant use.
b Multivariable Cox proportional regression analysis adjusting for age, sex, socio-economic sta
aspirin, hospitalization (days), and a diagnosis of clinical depression.considered relatively safe in comparison to the use of TCAs, especially
for patients with HF [24]. Most other studies found no signiﬁcant effect
of SSRI use in adjusted analyses on mortality [5,6,8–12], or even a signif-
icant decrease in the risk ofmortality [14,15]. Furthermore, two large ran-
domized clinical trials that enrolled patients with coronary artery disease
(i.e., Sertraline Against Depression and Heart Disease in Chronic Heart
Failure SADHART and the Canadian Cardiac Randomized Evaluation of
Antidepressant and Psychotherapy Efﬁcacy trial) found no safety issues
with SSRI use [6] Diez-Quevedo et al. did found similar results for ﬂuoxe-
tine, but found no signiﬁcant difference in the risk for sertraline and
escitalopram and even a tendency towards a lower mortality risk for
citalopram [5]. In relation to the TCAs, we found mixed ﬁndings in rela-
tion to mortality risk. This is similar to other ﬁndings with one study on
post myocardial infarction (MI) patients ﬁnding a lower but non-
signiﬁcant risk for mortality [15] while other studies found no signiﬁcant
increase in the risk for mortality after a ﬁrst-time MI or ischemic heart
disease [5,8,10,11]. For the group of other antidepressants, only the= 120,453)a,b.
tality CV mortality
95% CI P value HR 95% CI P value
1.03–1.24 .01 .96 .86–1.09 .55
.98–1.20 .12 .95 .84–1.08 .44
1.11–1.24 b.001 1.07 1.00–1.15 .05
1.17–1.23 b.001 1.14 1.11–1.18 b.001
1.19–1.37 b.001 1.58 1.45–1.73 b.001
1.04–1.28 .005 1.11 .97–1.26 .12
1.06–1.21 b.001 1.08 .99–1.17 .09
.90–1.21 .06 .97 .81–1.16 .72
.68–1.32 .74 .60 .38–.93 .02
.63–1.54 .93 1.05 .59–1.84 .87
1.07–1.25 b.001 1.12 1.01–1.24 .03
1.05–1.85 .02 1.55 .95–2.53 .08
1.16–.1.27 b.001 1.19 1.23–1.26 b.001
tus, etiology, HF severity, comorbidity, statins, beta blockers, ACE-inhibitors, spironolactone,
873C. Brouwers et al. / International Journal of Cardiology 203 (2016) 867–873study by Monster et al. found a protective effect in relation to the risk of
MI [12], with most other studies ﬁnding no signiﬁcant difference in risk
of use of other antidepressants in relation to MI [11,15], ischemic heart
disease [10] or mortality [8].
In relation to the SNRIs and NaSSAs, venlafaxine, duloxetine and
mirtazapine were also examined in previous studies in which no signif-
icant difference in risk on mortality was found [5,10].
4.1. Limitations
The results of the current study should be interpreted with the fol-
lowing limitations inmind. Themain limitation is inherent in the obser-
vational nature of the study, with lack of information on certain clinical
variables (e.g. left ventricular ejection fraction, New York Heart Associ-
ation (NYHA) functional classiﬁcation, smoking, alcohol consumption,
and body mass index). Furthermore, there was a large discrepancy be-
tween the number of patients receiving antidepressants in comparison
to the number of patients having a clinical depression. It could be that
depression was diagnosed in primary care and therefore not registered
in the national patient registry. Therefore, prescription of
antidepressants could be a proxy for (sub)clinical depression. Although
this study showed a substantially higher prevalence of clinical depres-
sion and use of antidepressants among women than among men, this
study did not take into account the gender differential in this cohort of
HF patients. Future studies are warranted to examine this gender differ-
ential in more detail, especially since some studies have raised the pos-
sibility that antidepressants may work somewhat differently in men
and women. Exposure to antidepressants was measured only once
(i.e., at 90 days post HF diagnosis), with the risk that study results
could have been biased towards the null because a patient's exposure
to medication may change over time. This approach was chosen, as
we did not have information on the duration of antidepressant treat-
ment use nor on the dosage. Furthermore, recorded prescriptions of
antidepressants are not necessarily equivalent to adherence with treat-
ment with consequences to prognosis, as shown in our study. Others
have shown that non-adherent and poor adherent patients have nopro-
tective effects of antidepressant use and are more likely to die prema-
turely, as compared to patients who have moderate and high
adherence levels.
5. Conclusion
In the current study, we found a high prevalence of antidepressant
use in HF patients, with and without a diagnosis of clinical depression,
subsequent to hospital discharge. Use of antidepressants increased
over time after diagnosis with HF, and use of antidepressants after hos-
pital dischargewas signiﬁcantly associatedwith a higher all-causemor-
tality risk, even when adjusting for socio-demographic and clinical
variables and diagnosis of depression. These results highlight the impor-
tance of further examining the antidepressant prescription pattern in
patients with HF patients, especially in those without a clinical depres-
sion. Future research should also seek to identify the unique pharmaco-
logical properties of individual antidepressants, as this may be crucial
for understanding the antidepressant effects on cardiac function and
mortality.
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